Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Reuters

2025/12/12

<a href="https://laohu8.com/S/ANIX">Anixa Biosciences</a> Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda®, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA45044) on December 11, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590542270"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590542270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590542270?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 07:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590542270","market":"fut","top_or_hot":-1,"title":"Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda®, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA45044) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-12 07:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda®, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA45044) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8JDq3Z:1","article_id":"2590542270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590542270","pubTimestamp":1765494140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANIX":"Anixa Biosciences"},"translate_title":"Anixa Biosciences报告研究性乳腺癌疫苗1期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIX":0.9},"content_text":"Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine\n    \n\n        Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda®, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA45044) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}